Phase 2A Antimalarial Pyrrolidinamide Trial in Adult Patients With P. Falciparum Malaria, NCT07545681
Summary
NIH registered Phase 2A clinical trial NCT07545681 evaluating GSK3772701 (a novel antimalarial pyrrolidinamide) in adult participants with uncomplicated Plasmodium falciparum malaria. The study will test five different dose levels (50 mg, 150 mg, 400 mg, 600 mg, and 900 mg) to assess safety and efficacy. This dose-escalation trial represents an early-stage efficacy study in the drug development pipeline.
“The study will evaluate the safety and efficacy of a new antimalarial drug GSK3772701 (a pyrrolidinamide), using different doses and treatment durations, in adult participants with uncomplicated Plasmodium (P.) falciparum malaria.”
About this source
ClinicalTrials.gov is the NIH-run registry of every clinical trial conducted in the United States, plus most international trials sponsored by US-based companies or institutions. By federal law, sponsors must register Phase 2 through Phase 4 studies before enrolling patients and post results within a year of completion. This feed tracks every new trial registration and study update, around 700 a month: drug interventions, device studies, behavioral protocols, observational research. Watch this if you scout drug candidates moving into mid or late-stage development, monitor competitor pipelines, or follow rare disease research where new trials signal patient hope. GovPing parses sponsor, phase, intervention, and target indication on each entry.
What changed
NIH registered a new Phase 2A clinical trial (NCT07545681) for GSK3772701, a novel antimalarial pyrrolidinamide compound, in adult patients with uncomplicated P. falciparum malaria. The trial will evaluate five dose levels (50 mg, 150 mg, 400 mg, 600 mg, and 900 mg) for safety and efficacy. Clinical investigators and pharmaceutical companies monitoring antimalarial drug development pipelines should note this trial as an early efficacy milestone in the development of a new malaria treatment candidate.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
A Phase 2A Study of a Novel Antimalarial Pyrrolidinamide in Adult Patients With Uncomplicated P. Falciparum Malaria
Phase 2 NCT07545681 Kind: PHASE2 Apr 22, 2026
Abstract
The study will evaluate the safety and efficacy of a new antimalarial drug GSK3772701 (a pyrrolidinamide), using different doses and treatment durations, in adult participants with uncomplicated Plasmodium (P.) falciparum malaria.
Conditions: Malaria, Falciparum
Interventions: GSK3772701 600 mg, GSK3772701 900 mg, GSK3772701 150 mg, GSK3772701 400 mg, GSK3772701 50 mg
Mentioned entities
Parties
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.